InterMune, Inc. (NASDAQ:ITMN)
The Company is a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
MKArch
(99.70)
Submitted: 4/21/2013 10:00:28 AM :
Start Price:
$8.99
ITMN Score:
+3.64
One Pipeline drug; binary proposition, that I'm taking a shot on based on M* analysis. Don't bet anything you can't afford to lose on this one.
Recs
NuclearSteve
(54.96)
Submitted: 4/12/2013 2:06:08 PM :
Start Price:
$9.39
ITMN Score:
+1.08
Baker brothers increased their holding.
Recs
zzlangerhans
(99.78)
Submitted: 2/27/2013 1:20:28 AM :
Start Price:
$8.41
ITMN Score:
+7.42
There's going to be a run-up in Intermune stock before topline data from the ASCEND trial in H1 2014. The only question is when the run will start, and from what share price. Two major overhangs to the run have recently been removed. The company has guided to predictably unimpressive 2013 European Esbriet revenues of 40-70M. That eliminates a lot of the nervousness about ongoing cost-effectiveness and pricing concerns in the major EU countries. Last month, the company raised 263M in a combination dilutive/debt financing that will provide them with sufficient funds to take them through topline data. That, of course, does not mean they won't raise again before completion of the study but they will almost certainly be looking for a higher share price. There's likely at least a year to go before data so this green thumb is a flag for a possible future buy at a lower price ahead of the run.
Recs
naughtyguy
(31.31)
Submitted: 2/24/2013 7:25:05 AM :
Start Price:
$8.93
ITMN Score:
+2.46
might be worth more than 1/2billion market cap??
Recs
Recs
SnarkyApple
(59.11)
Submitted: 9/17/2012 4:08:56 PM :
Start Price:
$9.69
ITMN Score:
-10.92
Shenanigans.
Recs
gopyerk
(80.71)
Submitted: 7/24/2012 9:57:10 AM :
Start Price:
$9.48
ITMN Score:
-18.78
I have watched this company for some time now and I like the direction provided in the comany relase for Q2 of 2012. While this is a small company with a very specific niche in the market right now, I think the room for growth is still good.
Recs
ghall3
(< 20)
Submitted: 4/23/2012 7:19:15 AM :
Start Price:
$9.94
ITMN Score:
-18.85
Lower price caused by essentially deferring profit to the future, but the profit will be there. Same thing that happened to them a few years ago.
Recs
SorrySam
(72.03)
Submitted: 4/21/2012 2:54:57 AM :
Start Price:
$12.12
ITMN Score:
-39.92
qvt financial who made blockbuster calls on mdvn, inhx, etc.
Recs
EclecticRecluse
(77.80)
Submitted: 3/23/2011 7:41:55 AM :
Start Price:
$43.86
ITMN Score:
+106.86
Low Sales and Few Employees for Capital
Recs
bg019818
(< 20)
Submitted: 12/31/2010 9:18:42 AM :
Start Price:
$36.78
ITMN Score:
-105.98
Breakthrough in its lung disease drug.
Recs
Recs
flipsmurf
(81.00)
Submitted: 6/14/2010 5:04:23 PM :
Start Price:
$9.75
ITMN Score:
-49.02
Great new product and way oversold at current price
Recs
Recs
jkok
(45.48)
Submitted: 5/6/2010 9:54:29 AM :
Start Price:
$13.01
ITMN Score:
-66.28
recently suffered
Recs
BlackshearFund
(< 20)
Submitted: 5/5/2010 7:30:47 PM :
Start Price:
$10.06
ITMN Score:
-44.02
Oversold. Might see 15's again soon.
Recs
Zolton7620
(< 20)
Submitted: 3/23/2010 3:28:50 AM :
Start Price:
$40.95
ITMN Score:
-118.75
The drug pirfenidone now under consideration by the FDA for approval for treatment of Idiopathic Pulmonary Function is also effective for MS and a number of other diseases yet to be fully tested.
Recs
Recs
bvdbreaker
(< 20)
Submitted: 10/8/2009 7:42:32 AM :
Start Price:
$14.06
ITMN Score:
-85.77
undervalued pipeline, period
Recs
pmtrain
(95.21)
Submitted: 2/10/2009 5:26:34 AM :
Start Price:
$18.62
ITMN Score:
-143.46
hpc trials are taking this company higher almost daily feb 2009 (best owned performer)
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 35 : 1 2 Next »